EUVIMEDEUVIMED entdecken
Crossref

Cell‐free and concentrated ascites reinfusion therapy versus large‐volume paracentesis for the treatment of cirrhotic patients with refractory ascites: A multicenter prospective observational study

Tatsunori Hanai iD, Hideto Kawaratani, Junji Nagano, Hirokazu Suii, Akira Sakamaki, Yoshitaka Arase, Hiroyuki Nakanishi, Tomomi Kogiso, Tomomi Okubo, Takao Miwa iD, Shogo Shimizu, Shuhei Hige und 7 weitere

Hepatology Research · 2023-03 · 53 (3) · 238-246

DOI: 10.1111/hepr.13860 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hepatology Research, online erschienen am 03.12.2022. Verfasst von Tatsunori Hanai und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology/Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Cell‐free and concentrated ascites reinfusion therapy (CART) and large‐volume paracentesis (LVP) with albumin infusion are useful for managing refractory ascites (RA). However, it remains unclear which therapy is more effective in patients with cirrhosis with RA.

Methods

From June 2018 to March 2022, 25 patients with RA treated with CART or LVP with albumin infusion were enrolled in this multicenter prospective observational study to investigate the number of abdominal paracenteses, albumin preparations used, and drainage volume during an 8‐week observation period.

Results

Among all patients at entry (median age, 63 years; 52% men; 60% Child–Pugh B and 40% Child–Pugh C), 92% were treated with furosemide (median, 20 mg/day), 92% with spironolactone (25 mg/day), and all with tolvaptan (7.5 mg/day). Patients with RA had a poor health‐related quality of life (HRQOL) and prominent ascites‐related symptoms. Four of the 20 eligible patients were treated with CART, 11 with LVP with albumin infusion, and five with their combination. The median number of paracenteses, total drainage volume, and albumin infusions were 1.5, 7.4 L, and 0, respectively, in the CART group; 5.0, 22.0 L, and 5.0, respectively, in the LVP group; and 5.0, 30.0 L, and 5.0, respectively in their combination group. The treatment effects did not differ significantly among the three groups regarding weight loss, liver function, renal function, electrolytes, and HRQOL. However, patients treated with CART had fewer paracenteses and albumin infusions than those treated with LVP.

Conclusions

CART and LVP have comparable therapeutic efficacy for RA in patients with cirrhosis.

Schlagwörter

Stichwörter der Autor:innen

complicated ascitesdiuretic-resistanceliver failurequality of liferefractory ascites

Autor:innen und Institutionen

  • Department of Gastroenterology/Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.
  • Department of Gastroenterology, Nara Medical University, Nara, Japan.
  • Department of Gastroenterology, Gifu Prefectural General Medical Center, Gifu, Japan.
  • Department of Gastroenterology, Sapporo Kosei General Hospital, Sapporo, Hokkaido, Japan.
  • Division of Gastroenterology and Hepatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan.

ORCID-Profile: Tatsunori Hanai, Takao Miwa

Zitieren

APA

Hanai, T., Kawaratani, H., Nagano, J., Suii, H., Sakamaki, A., Arase, Y., Nakanishi, H., Kogiso, T., Okubo, T., Miwa, T., Shimizu, S., Hige, S., Atsukawa, M., Shimizu, M., Kurosaki, M., Terai, S., Kagawa, T., Tokushige, K., & Yoshiji, H. (2023). Cell‐free and concentrated ascites reinfusion therapy versus large‐volume paracentesis for the treatment of cirrhotic patients with refractory ascites: A multicenter prospective observational study. Hepatology Research, 53(3), 238-246. https://doi.org/10.1111/hepr.13860

Vancouver

Hanai T, Kawaratani H, Nagano J, Suii H, Sakamaki A, Arase Y, et al. Cell‐free and concentrated ascites reinfusion therapy versus large‐volume paracentesis for the treatment of cirrhotic patients with refractory ascites: A multicenter prospective observational study. Hepatology Research. 2023;53(3):238-246. doi:10.1111/hepr.13860

BibTeX
@article{Hanai2023,
  author = {Hanai, Tatsunori and Kawaratani, Hideto and Nagano, Junji and Suii, Hirokazu and Sakamaki, Akira and Arase, Yoshitaka and Nakanishi, Hiroyuki and Kogiso, Tomomi and Okubo, Tomomi and Miwa, Takao and Shimizu, Shogo and Hige, Shuhei and Atsukawa, Masanori and Shimizu, Masahito and Kurosaki, Masayuki and Terai, Shuji and Kagawa, Tatehiro and Tokushige, Katsutoshi and Yoshiji, Hitoshi},
  title = {Cell‐free and concentrated ascites reinfusion therapy versus large‐volume paracentesis for the treatment of cirrhotic patients with refractory ascites: A multicenter prospective observational study},
  journal = {Hepatology Research},
  year = {2023},
  volume = {53},
  number = {3},
  pages = {238--246},
  doi = {10.1111/hepr.13860}
}
Kostenlos starten →